Pharmaceuticals News and Research

RSS

NCKU develops novel stem cell therapy for heart repair

Assistant Prof. Patrick C. H. Hsieh of Institute of Nanotechnology and Microsystems Engineering, College of Medicine, National Cheng Kung University (NCKU), Tainan, Taiwan, has led a research team of myocardial regeneration to conduct an experiment on pigs and has proved that by combining self-assembling peptide nanofiber hydrogel with autologous bone marrow stem cell, myocardial protection after acute myocardial infarction, vascular regeneration and heart functions can be improved.

12 Oct 2010

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Adeona Pharmaceuticals, Inc., announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer's disease and cognitive decline.

12 Oct 2010

Integrated Research Network to analyze payor health policy for chronic pain medications

HealthCore's Integrated Research Network is enrolling family physicians, general practitioners, internists, neurologists, rheumatologists, endocrinologists, and pain management specialists in a first-of-its-kind study to analyze payor health policy for chronic pain medications.

12 Oct 2010

DSM, BRAIN announce strategic cooperation to develop water-soluble vitamins

DSM Nutritional Products GmbH, a subsidiary of the Dutch company Royal DSM N.V., the world's primary supplier of vitamins, carotenoids and fine chemicals and BRAIN AG, one of the leading European white biotechnology companies, announced a strategic cooperation in the biotechnological production of water-soluble vitamins.

12 Oct 2010

An overview on Annual BioPartnering Europe 2010

TVG is pleased to welcome leading biotech and pharma executives at the 18th Annual BioPartnering Europe, held in London, UK. To open the conference, Dr. Anders Ekblom, Executive Vice President, Global Medicines Development at AstraZeneca, spoke about a commitment to innovation and AstraZeneca's unique approach to collaborations.

12 Oct 2010

UCB, Synosia Therapeutics announce new strategic partnership in neurology

UCB and Synosia Therapeutics announced today a new strategic partnership in neurology. Synosia has granted UCB a license for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications. Both are in Phase II clinical development for the treatment of Parkinson's disease.

12 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme.

12 Oct 2010

BioSystem Development completes $978,000 investment round

BioSystem Development, a privately held life science analytics company, announces a recently completed investment round that raised $978,000 (USD) in funding. The proceeds will be used to expand manufacturing infrastructure and to launch new products into the biopharmaceutical development market.

12 Oct 2010

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

Researchers in Canada and France have raised concerns about substantial inconsistencies in a basic aspect of the way Phase-I and Phase-II cancer clinical trials are designed.

11 Oct 2010

$Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer$

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

ZeroNines launches ZenVault Medical Personal Health Record portal

ZeroNines® Technology, Inc. announced the launch of ZenVault™ Medical, a Personal Health Record portal (PHR) that gives consumers instant, secure, private access to their medical records online. ZenVault Medical was specifically designed to address the public's concerns over data security, privacy, convenience, and expense associated with the national push to convert from traditional paper to digital medical records.

11 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.

11 Oct 2010

Generex to acquire majority interest in Global Medical Direct

Generex Biotechnology Corporation today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications.

11 Oct 2010

Obesity treatments falter, but researchers announce gene links

The Wall Street Journal: "An international research consortium says it has identified 18 new gene sites linked to obesity and 13 others associated with how fat is distributed in the body, advances that shed new light on the complex biology underlying one of the world's most pressing public-health problems. The findings are based on studies involving nearly 250,000 people, making the effort the largest so far to unravel the genetic basis of common human traits, researchers said.

11 Oct 2010

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

Health Robotics today announced that it recently signed exclusive distribution agreements for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies in seven new European countries with regional industry leaders Newico and Apta Medica, rapidly continuing on its worldwide quest to pervasively provide safe and cost-effective Intravenous (IV) Admixture Compounding Automation to hospitals all over the world.

11 Oct 2010

ImaginAb and Imanet enter master service agreement for pre-clinical and clinical imaging

ImaginAb, Inc. and Imanet have signed a master service agreement for pre-clinical and clinical imaging. This agreement supports the development strategy for ImaginAb's pipeline of next generation diagnostic imaging agents based on recombinant antibody fragments. The Imanet™ network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET research tracers.

11 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Attorney Keith Jensen of the Fort Worth, Texas-based law firm of Jensen, Belew & Gonzalez is announcing a $3.78 million settlement with pharmaceutical manufacturer Pfizer Inc. on behalf of the family of a nine-year-old New York girl who died in June 2004 as the result of a drug-induced disease known as Stevens Johnson Syndrome, which caused all of her skin to peel off.

11 Oct 2010

Pharmaceuticals News and Research

NCKU develops novel stem cell therapy for heart repair

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Integrated Research Network to analyze payor health policy for chronic pain medications

DSM, BRAIN announce strategic cooperation to develop water-soluble vitamins

An overview on Annual BioPartnering Europe 2010

UCB, Synosia Therapeutics announce new strategic partnership in neurology

Essentialis receives patent for active component in DCCR product

Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points

BioSystem Development completes $978,000 investment round

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

ZeroNines launches ZenVault Medical Personal Health Record portal

Access highlights clinical benefits of MuGard at ESMO conference

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

Generex to acquire majority interest in Global Medical Direct

Obesity treatments falter, but researchers announce gene links

Health Robotics enters distribution agreements with Newico and Apta Medica for 7 new European countries

ImaginAb and Imanet enter master service agreement for pre-clinical and clinical imaging

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence